Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin/Linagliptin FDC in T2DM
NCT01734785Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Feb 2013; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01734785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734785.